The women clearly preferred metformin to insulin treatment and there was no difference in the composite primary outcomes (p = 0.95), and even in the single outcomes included in the composite, severe hypoglycemia was less common in the metformin group (p = 0.008), but preterm birth was more common in the metformin group (p = 0.04). The gene discussed is INS; the disease is Hypoglycemia.